

The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users

Seonaid Nolan^{1,2}, Viviane Dias Lima^{1,2}, Nadia Fairbairn¹, Thomas Kerr^{1,2}, Julio Montaner^{1,2}, Jason Grebely^{1,3} & Evan Wood^{1,2}

British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, Canada,¹ Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada² and The Kirby Institute, University of New South Wales Australia, Sydney, NSW, Australia³

ABSTRACT

Aims To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users. **Design** A generalized estimating equation model assuming a binomial distribution and a logit-link function was used to examine for a possible protective effect of MMT use on HCV incidence. **Setting** Data from three prospective cohort studies of illicit drug users in Vancouver, Canada between 1996 and 2012. **Participants** A total of 1004 HCV antibody-negative illicit drug users stratified by exposure to MMT. **Measurements** Baseline and semi-annual HCV antibody testing and standardized interviewer-administered questionnaire soliciting self-reported data relating to drug use patterns, risk behaviors, detailed socio-demographic data and status of active participation in an MMT program. **Findings** One hundred and eighty-four HCV seroconversions were observed for an HCV incidence density of 6.32 [95% confidence interval (CI) = 5.44–7.31] per 100 person-years. After adjusting for potential confounders, MMT exposure was protective against HCV seroconversion [adjusted odds ratio (AOR) = 0.47; 95% CI = 0.29–0.76]. In subanalyses, a dose–response protective effect of increasing MMT exposure on HCV incidence (AOR = 0.87; 95% CI = 0.78–0.97) per increasing 6-month period exposed to MMT was observed. **Conclusion** Participation in methadone maintenance treatment appears to be highly protective against hepatitis C incidence among illicit drug users. There appears to be a dose–response protective effect of increasing methadone exposure on hepatitis C incidence.

Keywords HCV, hepatitis C, illicit drug use, incident infection, methadone, opioid, seroconversion.

Correspondence to: Evan Wood, University of BC, BC Centre for Excellence in HIV/AIDS, 608–1081 Burrard Street, Vancouver BC V6Z 1Y6, Canada. E-mail: uhri-ew@cfcenet.ubc.ca

Submitted 8 April 2014; initial review completed 11 June 2014; final version accepted 8 July 2014

INTRODUCTION

Hepatitis C virus (HCV) infection is a major global public health concern. Currently, more than 170 million people are infected [1–4] and between 3–4 million new infections occur annually world-wide [2]. Chronic HCV infection manifests in a variety of ways [5], with the major burden of serious illness resulting from cirrhosis and hepatocellular carcinoma (HCC) [1,3,6]. A substantial economic burden is associated with these conditions due to high morbidity and mortality and associated health-care costs. Specifically, more than 350 000 people die from HCV-related liver disease every year [2], and HCV infection is the leading cause for liver transplantations world-wide [7].

The risk of HCV infection is increased among people who use illicit drugs [8,9]. Furthermore, injection drug users (IDU) are at particularly high risk, with a global HCV prevalence of approximately 67% [10]. A major risk factor for HCV infection among IDU is through the sharing of injection equipment [11–13]. The 2013 reported incidence of HCV among IDU ranges from 10 to 40 cases per 100 person-years [13–15], with most infections occurring within 3 years of injection initiation [16]. To date, few interventions are proven to reduce the risk of HCV transmission among IDU [17]. Specifically, reviews of harm reduction strategies have shown needle exchange programs to likely be modestly effective in preventing HCV infection [18,19], whereas the evidence for opiate substitution treatment [e.g. methadone

maintenance treatment (MMT)], behavioral interventions and syringe disinfection is less convincing [20–22]. Among the reviews of addiction treatments, a recent systematic review and meta-analysis found that various forms of addiction treatment, including MMT, were not effective in reducing the risk of HCV [17]. The uncertainty regarding the effectiveness of MMT in preventing HCV is problematic, given the well-described barriers to its availability in many settings, and significant differences in the way in which methadone programs are delivered [23–25].

In British Columbia, Canada, MMT is widely available and can be prescribed by community physicians and dispensed through a network of community pharmacies [26]. While past studies have shown MMT to be associated with reductions in heroin injecting in this setting [27], analyses have not examined the impact of MMT on HCV incidence. We therefore conducted the present study to examine for a protective effect of MMT exposure on HCV seroconversion within a long-standing sample of illicit drug users.

METHODS

Sample

Data for this analysis were derived from three related prospective cohort studies of illicit drug users in Vancouver, Canada. All cohorts used identical methods for data collection to allow for combined analyses. Specifically, the At Risk Youth Study (ARYS), the Vancouver Injection Drug Users Study (VIDUS) and the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) are three open prospective cohorts of people who use illicit drugs. Described in detail previously [28–32], each cohort was populated through snowball sampling and extensive street outreach and participants were eligible for inclusion if they lived in the greater Vancouver region at enrolment, reported using an illicit drug other than marijuana in the past 30 days and provided written informed consent. Recruitment for VIDUS and ACCESS (individual studies of HIV-negative and HIV-positive drug users, respectively) began in 1996. ARYS, a cohort of drug-using street-involved youth between the ages of 14 and 26 years, began recruitment in 2005.

Measures

MMT exposure

At baseline and every 6-month follow-up interview, participants answered a standardized interviewer-administered questionnaire and HCV-negative participants provided blood samples for HCV. Data related to drug use patterns, risk behaviors, detailed socio-demographic

data and self-reported status of active participation in an MMT program are solicited. Participants are given a \$20 monetary honorarium after each study visit, provided with basic medical care by nurses and, if appropriate, referred to health-care services. The ARYS, VIDUS and ACCESS cohorts have been approved by the University of British Columbia/Providence Health Care research ethics board.

HCV antibody status

All participants who were HCV-negative at baseline and had had at least one follow-up visit to assess for HCV incidence between May 1996 and December 2012 were eligible for inclusion. HCV seroconversion, defined by an HCV antibody-negative test at enrolment followed by a subsequent HCV antibody-positive test, was the primary study outcome. Because HCV testing was performed every 6 months, as described previously [33], the date of seroconversion was estimated as the mid-point between the last HCV-negative and the first HCV-positive antibody test. As described above, methadone use was in reference to the last 6 months at each semi-annual follow-up visit and was treated as a time-updated covariate in the multivariate analysis. For those with HCV seroconversion, follow-up time was calculated from the first HCV-antibody negative test until the estimated date of HCV seroconversion, after which participants were censored. For those without HCV seroconversion, follow-up time was calculated from the first to the last HCV antibody-negative test observed during the study period. Individuals who did not seroconvert were censored at the last contact date, 31 December 2012, or at the death date, whichever came first. HCV incidence density and confidence intervals were calculated by the person-years method.

Covariates

Our primary independent variable of interest was enrolment in MMT (yes versus no), which was time-updated at each 6-month assessment based on self-report of having filled any methadone prescription in the prior 6 months. Other hypothesized factors associated with HCV incidence were determined a priori and included the following baseline characteristics: age (per year older), gender (male versus female), ethnicity (Caucasian versus other) and education defined as high school completion (yes versus no). Behaviors and exposures that were measured at baseline and repeatedly during each semi-annual follow-up were treated as time-dependent variables and included: unstable housing, defined as living in a single occupancy room in a hotel, a recovery house or treatment, hostel, shelter, jail or having no fixed address in the last 6 months (yes versus no), syringe borrowing, defined

as injecting with a used syringe in the last 6 months (yes versus no) and various measures of drug use in the last 6 months, including daily injecting of cocaine, heroin or methamphetamine (all yes versus no).

Statistical analyses

Initially, to describe the baseline study sample, we stratified the cohort based on the above variables and into those on or off MMT at baseline. Categorical variables were compared using Fisher's exact test, and continuous variables were compared using Wilcoxon's rank sum test.

The explanatory variables were selected a priori based on expert opinion and previous publications [27]. In the primary analysis, we examined the effect of MMT use in the last 6 months. Then, as a subanalysis, we assessed for a dose-response effect by defining the independent variable of interest as the number of 6-month periods the individual was enrolled in MMT.

We built a confounder model using the generalized estimating equation (GEE) methodology assuming a binomial distribution, a logit-link function and an unstructured correlation structure. The advantage of using this methodology is that it produces robust standard errors and takes into consideration the correlation of responses for each participant [34]. For both the primary and subanalyses, we sought to adjust for potential confounding due to possible within-cohort clustering or other cohort effects. In this study, we forced into the multivariate models a variable representing cohort of recruitment to control for heterogeneity across cohorts, a variable representing calendar year of recruitment to control for the cohort effect and a variable representing follow-up time to control for different follow-up durations.

Beyond the cohort variables that were forced into the multivariate models, other potential confounders were selected for inclusion in the final models using a conservative backward selection approach proposed by Maldonado & Greenland, which considered the magnitude of change in the coefficient of the methadone maintenance variable [29,35]. Specifically, starting with a fixed model which considered all available variables, potential confounders were dropped one at a time, using the relative change in the coefficient for the variable related to the MMT variable as a criterion, until the maximum change from the full model exceeded 5%.

RESULTS

A total of 3741 participants were recruited between May 1996 and December 2012. Overall, baseline HCV prevalence was 63.1%. At baseline, the prevalence of HCV was 24% among those enrolled in MMT and was 76% among

those not enrolled in MMT ($P < 0.01$). Of the 1379 (36.9%) individuals who were HCV antibody-negative at baseline, 1004 (72.8%) had at least one follow-up visit to assess for HCV incidence and were therefore eligible for the present study. In comparison to the 375 (27.2%) participants who were HCV-negative at baseline and were excluded from the analyses of HCV incidence due to inadequate follow-up, the 1004 individuals included in these analyses were more likely to be non-white and older (both $P < 0.05$), although they did not differ by gender ($P = 0.248$) and MMT use at baseline ($P = 0.891$).

Table 1 provides baseline characteristics of the study population stratified by baseline MMT use. Only 55 (5.5%) individuals were on MMT at baseline. Within the cohort, the median year of MMT initiation was 2006 [interquartile range (IQR) = 2003–2009]. Participants on MMT at baseline had characteristics that implied a history of more experienced and entrenched drug use, as they were older, had at least a high school education and were more likely to report daily cocaine injection, heroin injection and methamphetamine injection in the preceding 6 months. There were no statistically significant differences on the basis of gender, ethnicity, housing status or reported syringe borrowing at baseline.

Overall, median follow-up was 2.1 years (25th–75th percentiles 1.1–3.6 years). A total of 111 (11%) participants initiated MMT during follow-up. The median number of 6-month intervals where MMT use was reported was two (25th–75th percentiles 1–6).

As of December 2012, 184 HCV seroconversions were observed for an incidence density of 6.32 [95% confidence interval (CI) = 5.44–7.31] per 100 person-years. Among those on MMT at baseline, 14 HCV seroconversions were observed (incidence density 0.48 per 100 person-years; 95% CI = 0.26–0.81 per 100 person-years) and 170 among those not on MMT at baseline (incidence density 5.84 per 100 person-years; 95% CI = 5.00–6.79 per 100 person-years). Moreover, cumulative MMT exposure was found to further reduce the risk of HCV seroconversion. Among those with no methadone exposure throughout follow-up, the incidence density was 5.46 (95% CI = 4.65–6.38) per 100 person-years, whereas it was 0.52 (95% CI = 0.29–0.85) per 100 person-years among those reporting methadone at one follow-up, and 0.34 (95% CI = 0.16–0.63) per 100 person-years among those reporting methadone at two or more follow-up visits.

Table 2 shows the results of the GEE regression analysis of factors associated with HCV seroconversion. MMT use had a statistically significant protective effect against HCV seroconversion in the multivariate [adjusted odds ratio (AOR) = 0.47; 95% CI = 0.29–0.76] analyses after adjustment for unstable housing, cocaine injection, heroin injection, methamphetamine injection, cohort of

Table 1 Baseline characteristics of hepatitis C virus (HCV)-negative participants, seen between 1996 and 2012, Vancouver, Canada stratified by use of methadone ($n = 1004$).

Characteristic	No methadone use	Methadone use	P-value
	$n = 949$ (%)	$n = 55$ (%)	
Age			
Median (IQR)	23 (20–25)	34 (23–43)	<0.001
Gender			
Female	287 (30)	20 (36)	0.367
Male	662 (70)	35 (64)	
Caucasian ethnicity			
Yes	594 (62.6)	39 (70.9)	0.251
No	355 (37.4)	16 (29.1)	
High school education or greater			
Yes	493 (51.9)	19 (34.5)	0.013
No	456 (48.1)	36 (65.5)	
Unstable housing*			
Yes	646 (68.1)	33 (60.0)	0.236
No	303 (31.9)	22 (40.0)	
Syringe borrowing*			
Yes	114 (12.1)	9 (16.4)	0.394
No	834 (87.9)	46 (83.6)	
Cocaine injection*			
Yes	230 (24.2)	24 (43.6)	0.002
No	719 (75.8)	31 (56.4)	
Heroin injection*			
Yes	304 (32.0)	43 (78.2)	<0.001
No	645 (68.0)	12 (21.8)	
Methamphetamine injection*			
Yes	97 (10.2)	11 (20.0)	0.040
No	852 (89.2)	44 (80.0)	

IQR = interquartile range. *Denotes activities in the previous 6 months.

Table 2 Generalized estimating equation (GEE) logistic regression analysis of factors associated with hepatitis C virus (HCV) sero-conversion among participants in Vancouver, Canada, 1996–2012 ($n = 1004$).

Characteristic	Unadjusted OR (95% CI)	Adjusted OR** (95% CI)
Methadone treatment		
Yes versus no	0.67 (0.45–0.99)	0.47 (0.29–0.76)
Age		
Per year older	0.99 (0.98–1.01)	0.99 (0.97–1.02)
Gender		
Female versus male	1.60 (1.17–2.17)	1.38 (0.90–2.10)
Caucasian ethnicity		
Yes versus no	1.10 (0.81–1.50)	1.16 (0.78–1.73)
Unstable housing		
Yes versus no	2.03 (1.51–2.73)	1.83 (1.30–2.59)
Cocaine injection*		
Yes versus no	4.67 (3.55–6.15)	2.46 (1.65–3.66)
Heroin Injection*		
Yes versus no	4.61 (3.42–6.21)	2.21 (1.44–3.40)
Methamphetamine injection*		
Yes versus no	2.59 (1.83–3.68)	3.77 (2.41–5.89)

OR = odds ratio; CI = confidence interval. *Denotes activities in the previous 6 months. **Estimates also adjusted for cohort of recruitment, calendar year of recruitment and follow-up time for each participant.

recruitment, calendar year of recruitment and follow-up time. A similar protective effect of methadone on HCV incidence was observed among those participants aged less than 30 years at baseline (AOR = 0.55; 95% CI = 0.31–0.99).

In subanalyses, we found a dose–response protective effect of increasing MMT exposure, measured as the number of 6-month periods that individuals were enrolled in MMT on HCV incidence in both the unadjusted (unadjusted OR = 0.89; 95% CI = 0.81–0.99) analysis and after adjustment for unstable housing, syringe borrowing, cocaine injection, cohort of recruitment, calendar year of recruitment and follow-up time (AOR = 0.87; 95% CI = 0.78–0.97).

DISCUSSION

The present study demonstrated a high incidence of HCV seroconversion among drug users in this setting. Furthermore, enrolment in MMT was found to be independently protective after adjustment for a range of socio-demographic and drug use characteristics, including unstable housing, syringe borrowing and daily injection of cocaine, heroin and crystal methamphetamine. Additionally, despite higher-risk drug users being attracted into MMT use, the protective effect was maintained with a prolonged duration of MMT exposure in a dose-dependent fashion.

Although high rates of HCV among drug users have been reported previously [10,36,37], the literature investigating the effect of MMT on HCV incidence in this patient population is scarce. While MMT use has been shown to decrease self-reported high-risk behaviors associated with blood-borne infection among this population, including frequency of heroin injection, needle or syringe sharing and unsafe sex [4,38], the evidence that MMT itself reduces HCV incidence has been mixed. As described above, a meta-analysis published in 2011 [17] was able to identify only eight studies which examined the impact of opioid replacement therapy on HCV incidence, with the overall effect not reaching statistical significance. This may be explained by the heterogeneity of the studies included, as they were conducted in a variety of settings ranging from a general practitioner's office to an incarcerated male population [39,40]. Additionally, the sample sizes ($n = 54$ – 468) and number of HCV seroconversions ($n = 7$ – 39) were small. Lastly, these studies were of short duration, with typical follow-up periods of less than 5 years. The limitations of such short follow-up periods when assessing intervention impacts on HCV incidence have been reported previously [17]. A more recent analysis, which pooled data from six settings in the United Kingdom, found that opioid substitution therapy was associated with a 60% reduction in new HCV

infections [41]. These findings, however, were limited, as only 40 HCV seroconversions were observed throughout the study period. The present study was conducted among a large community-recruited cohort in a setting where access to MMT is less restricted than in the United States, as it is provided in office practices and dispensed through community pharmacies [26]. Among a population that experienced 184 HCV seroconversions, we found that MMT use was associated independently with reduced HCV incidence and that greater MMT exposure had a dose–response effect on reducing HCV infections.

Our study has limitations. First, as there are no registries of drug-user populations in our setting, the study sample was not a random sample. Secondly, as this was an observational study, we cannot infer causation and it is possible that unmeasured confounders explain our findings. In particular, although those prescribed MMT generally had a profile that would predict higher risk of HCV, comparison of medication outcomes in non-randomized trials raises concerns regarding unmeasured confounding. However, a randomized trial that investigated the impact of MMT on HCV infection rates would raise feasibility issues due to duration of follow-up required to demonstrate an effect. More importantly, this would raise ethical concerns due to non-provision of MMT, given its proven benefits in the treatment of heroin addiction [42,43]. Use of a needle exchange facility is another potential confounder; however, past analyses have demonstrated selection effects and inaccuracies in measuring this variable in our setting [44]. Thirdly, the variables in our study often relied upon self-report and are behaviors of a socially sensitive nature, and therefore may be subject to under-reporting as a consequence of either recall or social desirability bias [45]. While some drug use behaviors and other variables may be collinear, given that both the univariable and multivariable models produced similar odds ratios (with the same direction and strength) for each explanatory variable, we are reassured and feel confident that multi-collinearity did not influence our final results. Finally, in some settings buprenorphine/naloxone is more widely available than MMT, and we were unable to assess the impact of this medication due to its infrequent use in this setting [26].

In conclusion, we found a strong protective effect of MMT on HCV incidence among a long-standing cohort of drug users in a Canadian setting. We also found a dose–response protective effect of increasing MMT exposure on HCV incidence. Our results add to the known benefits of MMT on reducing the harms associated with heroin and other drug use [42,43]. These findings have important implications for health-care systems and settings which continue to limit the availability of MMT [46,47].

Declaration of interests

None.

Acknowledgements

The authors thank the study participants for their contribution to the research, as well as current and past researchers and staff. We thank Deborah Graham, Peter Vann, Tricia Collingham, Cody Callon, Jennifer Matthews, Guillaume Colley, Sabina Dobrer, Caitlin Johnston, Jenny Matthews and Steve Kain for their research and administrative assistance. This research was undertaken, in part, thanks to funding from the Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine which supports E.W. V.D.L. is supported by a Scholar Award from the Michael Smith Institute for Health Research, a New Investigator Award from CIHR and two grants from CIHR (MOP-125948) and NIDA (R03DA033851-01). J.G. is supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship. J.M. is supported by the British Columbia Ministry of Health and the US National Institutes of Health (R01DA036307). He has also received limited unrestricted funding from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare. This study was supported through the US National Institutes on Drug Abuse through R01 grants that support the ARYS (R01DA028532), VIDUS (R01DA011591) and ACCESS (R01DA021525) studies.

References

- Haydon E., Fischer B., Kraiden M. *Hepatitis C virus (HCV) infection and illicit drug use* [Internet]. Ottawa: Canadian Centre of Substance Abuse. 2005 (cited 18 January 2014). Available at: <http://www.ccsa.ca/Resource%20Library/ccsa-004030-2005.pdf> (accessed 19 June 2014) (archived at <http://www.webcitation.org/6QS7hPs7j> on 19 June 2014).
- Mohd Hanafiah K., Groeger J., Flaxman A. D., Wiersma S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 2013; **57**: 1333–42.
- Fischer B. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach—the case study of Canada. *J Urban Health* 2004; **81**: 428–47.
- Alavian S.-M., Mirahmadizadeh A., Javanbakht M., Keshtkaran A., Heidari A., Mashayekhi A. *et al.* Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. *Hepat Mon* 2013; **13**: 1–6.
- Seeff L. B. Natural history of hepatitis C. *Hepatology* 1997; **26**: 21S–8.
- Perz J. F., Armstrong G. L., Farrington L. A., Hutin Y. J. F., Bell B. P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; **45**: 529–38.
- Dinner K., Donaldson T., Potts J., Sirna J., Wong T. Hepatitis C: a public health perspective and related implications for physicians. Public Health Agency of Canada. *R Coll Outlook* 2005; **2**: 20–2.
- Alter M. J., Kruszon-Moran D., Nainan O. V., McQuillan G. M., Gao E., Moyer L. A. *et al.* The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999; **341**: 556–62.
- Hajarizadeh B., Grebely J., Dore G. J. Epidemiology and natural history of HCV infection. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 553–62.
- Nelson P. K., Mathers B. M., Cowie B., Hagan H., Jarlais D., Horyniak D. *et al.* Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; **378**: 571–83.
- Hagan H., Pouget E. R., Williams I. T., Garfein R. L., Strathdee S. A., Hudson S. M. *et al.* Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. *J Infect Dis* 2010; **201**: 378–85.
- Roy E., Alary M., Morissette C., Leclerc P., Boudreau J.-F., Parent R. *et al.* High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. *Int J STD AIDS* 2007; **18**: 23–7.
- Maher L., Jalaludin B., Chant K. G., Jayasuriya R., Sladden T., Kaldor J. M. *et al.* Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. *Addiction* 2006; **101**: 1499–508.
- Page K., Hahn J. A., Evans J., Shiboski S., Lum P., Delwart E. *et al.* Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. *J Infect Dis* 2009; **200**: 1216–26.
- Bruneau J., Roy E., Arruda N., Zang G., Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. *Addiction* 2012; **107**: 1318–27.
- Roy E., Boudreau J.-F., Boivin J.-F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. *Drug Alcohol Depend* 2009; **102**: 158–61.
- Hagan H., Pouget E. R., Des Jarlais D. C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. *J Infect Dis* 2011; **204**: 74–83.
- Somainsi B., Wang J., Perozo M., Kuhn E., Meili D., Grob P. *et al.* A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. *AIDS Care* 2000; **12**: 449–60.
- Taylor A., Goldberg D., Hutchinson S., Cameron S., Gore S. M., McMenamin J. *et al.* Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990–1996: are current harm reduction strategies working? *J Infect* 2000; **40**: 176–83.
- Craine N., Hickman M., Parry J. V., Smith J., Walker A. M., Russell D. *et al.* Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. *Epidemiol Infect* 2009; **137**: 1255–65.
- Vickerman P., Martin N., Turner K., Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. *Addiction* 2012; **107**: 1984–95.

22. McGowan C., Harris M., Rhodes T. Hepatitis C avoidance in injection drug users: a typology of possible protective practices. *PLOS ONE* 2013; **8**: e77038.
23. Fairbairn N., Hayashi K., Kaplan K., Suwannawong P., Qi J., Wood E. *et al.* Factors associated with methadone treatment among injection drug users in Bangkok, Thailand. *J Subst Abuse Treat* 2012; **43**: 108–13.
24. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. *Lancet* 2010; **376**: 285–301.
25. Mathers B. M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R. P. *et al.* HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. *Lancet* 2010; **375**: 1014–28.
26. Nosyk B., Sun H., Evans E., Marsh D. C., Anglin M. D., Hser Y.-I. *et al.* Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. *Addiction* 2012; **107**: 1621–9.
27. Kerr T., Marsh D., Li K., Montaner J., Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. *Drug Alcohol Depend* 2005; **80**: 329–35.
28. Strathdee S. A., Palepu A., Cornelisse P. G., Yip B., O'Shaughnessy M. V., Montaner J. S. *et al.* Barriers to use of free antiretroviral therapy in injection drug users. *JAMA* 1998; **280**: 547–9.
29. Wood E., Hogg R. S., Lima V. D., Kerr T., Yip B., Marshall B. D. L. *et al.* Highly active antiretroviral therapy and survival in HIV-infected injection drug users. *JAMA* 2008; **300**: 550–4.
30. Wood E., Hogg R. S., Bonner S., Kerr T., Li K., Palepu A. *et al.* Staging for antiretroviral therapy among HIV-infected drug users. *JAMA* 2004; **292**: 1175–7.
31. Wood E., Stoltz J.-A., Montaner J. S. G., Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. *Harm Reduct J* 2006; **3**: 18.
32. Kerr T., Small W., Johnston C., Li K., Montaner J. S. G., Wood E. Characteristics of injection drug users who participate in drug dealing: implications for drug policy. *J Psychoact Drugs* 2008; **40**: 147–52.
33. DeBeck K., Kerr T., Li K., Fischer B., Buxton J., Montaner J. *et al.* Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. *Can Med Assoc J* 2009; **181**: 585–9.
34. Diggle P. J., Heagerty P., Liang K. Y., Zeger S. L. *Analysis of Longitudinal Data*, 2nd edn. Oxford, UK: Oxford University Press; 2002.
35. Maldonado G., Greenland S. Simulation study of confounder-selection strategies. *Am J Epidemiol* 1993; **138**: 923–36.
36. Miller C. L., Johnston C., Spittal P. M., Li K., Laliberte N., Montaner J. *et al.* Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. *Hepatology* 2002; **36**: 737–42.
37. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. *Subst Use Misuse* 1998; **33**: 1197–212.
38. Noori R., Narenjiha H., Aghabakhshi H., Habibi G., Khoshkrood Mansoori B. Methadone maintenance therapy outcomes in Iran. *Subst Use Misuse* 2012; **47**: 767–73.
39. Dolan K. A., Shearer J., White B., Zhou J., Kaldor J., Wodak A. D. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. *Addiction* 2005; **100**: 820–8.
40. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. *Addiction* 1997; **92**: 999–1005.
41. Turner K. M. E., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N. *et al.* The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. *Addiction* 2011; **106**: 1978–88.
42. Mattick R. P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009; **3**: CD002209.
43. Gowing L. R., Farrell M., Bornemann R., Sullivan L. E., Ali R. L. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. *J Gen Intern Med* 2006; **21**: 193–5.
44. Schechter M. T., Strathdee S. A., Cornelisse P. G., Currie S., Patrick D. M., Rekart M. L. *et al.* Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. *AIDS* 1999; **13**: F45–51.
45. Des Jarlais D., Paone D., Milliken J., Turner C., Miller C., Gribble J. *et al.* Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. *Lancet* 1999; **353**: 1657–61.
46. Jurgens R., Csete J., Amon J. J., Baral S., Beyrer C. People who use drugs, HIV, and human rights. *Lancet* 2010; **376**: 475–85.
47. Nosyk B., Anglin M. D., Brissette S., Kerr T., Marsh D. C., Schackman B. R. *et al.* A call for evidence-based medical treatment of opioid dependence in the United States and Canada. *Health Aff (Millwood)* 2013; **32**: 1462–9.